Why the study?
It was hypothesized that the OVLT mediates changes in the gut microbiome associated with concomitant hypertension induced by AngII.
Does electrolytic lesion of the OVLT attenuate AngII-induced hypertension and alter the gut microbiome in rats on a high-salt diet?
RCT (n=34)
Randomly assigned
Does electrolytic lesion of the OVLT attenuate AngII-induced hypertension and alter the gut microbiome in rats on a high-salt diet?
Answers are grounded in this paper and cite their sources.
Electrolytic lesion of the OVLT attenuates AngII-salt hypertension and restores gut microbiome composition in rats, suggesting a brain-gut microbiome axis in hypertension.
Hypertension is a complex disorder shaped by both genetic predisposition and environmental influences. Growing evidence suggests that gut microbe–host interactions may influence the development of hypertension. The AngII-salt model of hypertension is known to have a neurogenic component thought to be linked to increased sympathetic nervous system activity. Indeed, we have shown the hypertensive response in AngII-salt treated rats requires the hypothalamic organum vasculosum of the lamina terminalis (OVLT), a circumventricular organ that has direct neural connections to increase sympathetic activity. Currently, we hypothesize the OVLT mediates changes in the gut microbiome associated with concomitant hypertension induced by ANGII. Male Sprague-Dawley rats (n = 6–12/group) with free access to a 2.0% NaCl diet were randomly assigned to receive an electrolytic lesion of the OVLT (OVLTx) or a sham procedure. One week later, rats were implanted with telemeters for continuous recording of mean arterial pressure (MAP). Following another week of recovery, animals received subcutaneous minipumps delivering either ANG II (150 ng/kg/min) or saline, generating four groups: sham-OVLT–saline (n=6), sham-OVLT–ANG II (n=8), OVLTx–saline (n=8), and OVLTx–ANG II (n=12). MAP was recorded for 12 days post-infusion. At study completion, rats were euthanized for gut collection and microbiome analysis, followed by brain perfusion with 4% PFA to verify lesion placement. At the end of the protocol, MAP was significantly (p< 0.001) higher in sham-OVLT-ANGII (131±3.7 mmHg) compared to sham OVLT-saline (101±1.8 mmHg) and OVLTx-saline (100±1.8 mmHg) control rats. In contrast, while MAP rose significantly in OVLTx–ANG II rats compared to saline control treated rats, by day 8 of AngII treatment, MAP was lower in OVLTx–ANG II rats (122.8±4.7 mmHg) compared to sham-OVLT-ANG II rats (131.9±4.3 mmHg). Consistent with our previous finding that OVLTx attenuates chronic AngII hypertension, this lower MAP observed in OVLTx–ANG II rats compared to sham-OVLT–ANG II rats remained a trend throughout the end of the protocol. With regard to the gut microbiome, genus level bacterial differences were noted between treatment groups. Increased levels of Lactobacillus species were noted in OVLTx–ANG II rats (as well as the two saline treated control groups) compared to sham-OVLT-rats in all four gut tissues sampled. Additionally, an increased abundance of Staphylococcus species was observed in sham-OVLT-ANGII rats compared to OVLTx–ANG II rats (as well as the two saline treated control groups) in all four gut tissues sampled. The altered microbiome in sham-OVLT-ANGII rats was restored to similar levels as saline control treated rats in OVLTx–ANG II rats. These results suggest an altered brain gut microbiome axis in OVLTx rats that may contribute to the attenuation of the hypertensive effects of AngII in OVLT lesioned rats. Supported by: JPC is funded by University of Minnesota College of Veterinary Medicine Internal Grant. This abstract was presented at the American Physiology Summit 2026 and is only available in HTML format. There is no downloadable file or PDF version. The Physiology editorial board was not involved in the peer review process.
No takes yet. Share an insight, caveat, or question.
Lauar et al. (2026) conducted an RCT in Hypertension (n=34). Electrolytic lesion of the OVLT (OVLTx) and ANG II infusion vs. Sham procedure and/or saline infusion was evaluated on Mean arterial pressure (MAP) at day 8 of AngII treatment.
Synapse has enriched 10 related papers. Consider them for comparative context: